elvn: the income statement

MyFinsight

Enliven Therapeutics, Inc. (ELVN)

For the quarter ending 2025-06-30, ELVN made $3,251K in revenue. -$25,496K in net income. Net profit margin of -784.25%.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

	2025-06-30
Net unrealized losses on marketable securities	-161
Research and development	21,491
General and administrative	7,093
Total operating expenses	28,584
Loss from operations	-28,584
Other expense	-2
Interest income	3,251
Income tax expense	-
Change in fair value of contingent value right liability	-
Total other income (expense), net	3,249
Net loss	-25,335
Comprehensive loss	-25,496

Net loss per share, basic	-0.49
Net loss per share, diluted	-0.49
Weighted average number of shares outstanding, basic	52,105,052
Weighted-average shares outstanding, diluted	52,105,052

Unit: Thousand (K) dollars (except for numbers of shares and EPS)